Calmark signs agreement with new distributor for Saudi Arabia

Calmark Sweden AB (publ) today signed an exclusive distributor agreement with the company Ajlan & Bros Holding Group Abilitii regarding marketing and sales of Calmark's Neo products in Saudi Arabia. Through the new agreement, Calmark will have several partners in the Middle East, which will spread the risks and speed up the launch.
 

The new agreement with Ajlan & Bros Holding Group Abilitii enters into force today and replaces the exclusive distributor agreement for Saudi Arabia signed in March 2021 with Enox Pharma AB.

Ajlan & Bros Holding Group is one of the largest investment and commercial groups in the Middle East region, employing over 15 000 people in more than 25 countries and across 75 companies. Established originally as a textile business in 1979, Ajlan & Bros has expanded into a conglomerate with a variety of sectors. 

The group invests in international companies in several countries and aims to become a regional leader in selected sectors. In addition to the healthcare sector, the group also invests in: energy, infrastructure, mining, financial services, facility management, logistics, textile, entertainment, tourism and education.

Ajlan & Bros Holding Group Abilitii is working on acquiring hospitals and medical centers. The aim is to support the modernization of Saudi Arabia, to provide world class healthcare practices with the latest methods of treatment and the best medical equipment.

"I am proud that we have established a partnership with this large company group, which is investing heavily in the healthcare sector," says Magdalena Tharaldsen, Director International Business Development for Calmark. "With Ajlan & Bros Holding Group Abilitii's large sales force, we are making a restart in Saudi Arabia. The conditions are good to get out quickly and widely with our products.”

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.

This disclosure contains information that Calmark Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 09-08-2022 16:16 CET.

For more information about Calmark Sweden AB, please contact:

Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se 
www.calmark.se 

Calmark Sweden AB is a medical technology company that develops and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark sells a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.